Advanced search
Publication Cover
Acta Oncologica Volume 41, 2002 - Issue 7-8
Journal homepage
374
Views
32
CrossRef citations to date
0
Altmetric
Research Article

Cytotoxic Treatment of Aggressive Prostate Tumors with or without Neuroendocrine Elements

Gunnar Steineck From the Genitourinary Oncology Service, Division of Solid Tumor Oncology, Department of Medicine (G. Steineck, W.K. Kelly, R. Frank, H.I. Scher), the Departments of Pathology (V. Reuter) and Radiology (L. Schwartz), Memorial Sloan Kettering Cancer Center, New York, Clinical Cancer Epidemiology, Department of Oncology Pathology (G. Steineck), Karolinska Institutet, Stockholm, Sweden, Department of Medicine (W.K. Kelly, H.I. Scher), Cornell University Medical College, New York
,
Victor Reuter From the Genitourinary Oncology Service, Division of Solid Tumor Oncology, Department of Medicine (G. Steineck, W.K. Kelly, R. Frank, H.I. Scher), the Departments of Pathology (V. Reuter) and Radiology (L. Schwartz), Memorial Sloan Kettering Cancer Center, New York, Clinical Cancer Epidemiology, Department of Oncology Pathology (G. Steineck), Karolinska Institutet, Stockholm, Sweden, Department of Medicine (W.K. Kelly, H.I. Scher), Cornell University Medical College, New York
,
William K. Kelly From the Genitourinary Oncology Service, Division of Solid Tumor Oncology, Department of Medicine (G. Steineck, W.K. Kelly, R. Frank, H.I. Scher), the Departments of Pathology (V. Reuter) and Radiology (L. Schwartz), Memorial Sloan Kettering Cancer Center, New York, Clinical Cancer Epidemiology, Department of Oncology Pathology (G. Steineck), Karolinska Institutet, Stockholm, Sweden, Department of Medicine (W.K. Kelly, H.I. Scher), Cornell University Medical College, New York
,
Richard Frank From the Genitourinary Oncology Service, Division of Solid Tumor Oncology, Department of Medicine (G. Steineck, W.K. Kelly, R. Frank, H.I. Scher), the Departments of Pathology (V. Reuter) and Radiology (L. Schwartz), Memorial Sloan Kettering Cancer Center, New York, Clinical Cancer Epidemiology, Department of Oncology Pathology (G. Steineck), Karolinska Institutet, Stockholm, Sweden, Department of Medicine (W.K. Kelly, H.I. Scher), Cornell University Medical College, New York
,
Larry Schwartz From the Genitourinary Oncology Service, Division of Solid Tumor Oncology, Department of Medicine (G. Steineck, W.K. Kelly, R. Frank, H.I. Scher), the Departments of Pathology (V. Reuter) and Radiology (L. Schwartz), Memorial Sloan Kettering Cancer Center, New York, Clinical Cancer Epidemiology, Department of Oncology Pathology (G. Steineck), Karolinska Institutet, Stockholm, Sweden, Department of Medicine (W.K. Kelly, H.I. Scher), Cornell University Medical College, New York
&
Howard I. Scher From the Genitourinary Oncology Service, Division of Solid Tumor Oncology, Department of Medicine (G. Steineck, W.K. Kelly, R. Frank, H.I. Scher), the Departments of Pathology (V. Reuter) and Radiology (L. Schwartz), Memorial Sloan Kettering Cancer Center, New York, Clinical Cancer Epidemiology, Department of Oncology Pathology (G. Steineck), Karolinska Institutet, Stockholm, Sweden, Department of Medicine (W.K. Kelly, H.I. Scher), Cornell University Medical College, New York
Pages 668-674 | Published online: 08 Jul 2009

Citations (32)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (1)

M. Francesca Monn & Liang Cheng. (2016) Emerging trends in the evaluation and management of small cell prostate cancer: a clinical and molecular perspective. Expert Review of Anticancer Therapy 16:10, pages 1029-1037.
Read now

Articles from other publishers (31)

Olga Kouroukli, Vasiliki Bravou, Konstantinos Giannitsas & Vasiliki Tzelepi. (2024) Tissue-Based Diagnostic Biomarkers of Aggressive Variant Prostate Cancer: A Narrative Review. Cancers 16:4, pages 805.
Crossref
Lukas Donix, Holger H. H. Erb, Claudia Peitzsch, Anna Dubrovska, Manuel Pfeifer, Christian Thomas, Susanne Fuessel & Kati Erdmann. (2022) Acquired resistance to irradiation or docetaxel is not associated with cross-resistance to cisplatin in prostate cancer cell lines. Journal of Cancer Research and Clinical Oncology 148:6, pages 1313-1324.
Crossref
Landon C. Brown, Susan Halabi, Jason A. Somarelli, Michael Humeniuk, Yuan Wu, Taofik Oyekunle, Lauren Howard, Jiaoti Huang, Monika Anand, Catrin Davies, Prekshaben Patel, Janet Staats, Kent J. Weinhold, Michael R. Harrison, Tian Zhang, Daniel J. George & Andrew J. Armstrong. (2022) A phase 2 trial of avelumab in men with aggressive-variant or neuroendocrine prostate cancer. Prostate Cancer and Prostatic Diseases 25:4, pages 762-769.
Crossref
Jacob E. Berchuck, Paul V. Viscuse, Himisha Beltran & Ana Aparicio. (2021) Clinical considerations for the management of androgen indifferent prostate cancer. Prostate Cancer and Prostatic Diseases 24:3, pages 623-637.
Crossref
Richard J. Rebello, Christoph Oing, Karen E. Knudsen, Stacy Loeb, David C. Johnson, Robert E. Reiter, Silke Gillessen, Theodorus Van der Kwast & Robert G. Bristow. (2021) Prostate cancer. Nature Reviews Disease Primers 7:1.
Crossref
Igor Tsaur, Isabel Heidegger, Alexander Kretschmer, Hendrik Borgmann, Giorgio Gandaglia, Alberto Briganti, Pieter de Visschere, Romain Mathieu, Massimo Valerio, Roderick van den Bergh, Piet Ost, Cristian Mirvald, Derya Tilki, Guillaume Ploussard & Cristian Surcel. (2019) Aggressive variants of prostate cancer – Are we ready to apply specific treatment right now?. Cancer Treatment Reviews 75, pages 20-26.
Crossref
Samson W Fine. (2018) Neuroendocrine tumors of the prostate. Modern Pathology 31, pages 122-132.
Crossref
Luca Campedel, Myriam Kossaï, Paul Blanc-Durand, Morgan Rouprêt, Thomas Seisen, Eva Compérat, Jean-Philippe Spano & Gabriel Malouf. (2017) Le cancer de la prostate neuro-endocrine : histoire naturelle, caractéristiques moléculaires, prise en charge et perspectives. Bulletin du Cancer 104:9, pages 789-799.
Crossref
Heba Alshaker, Qi Wang, Yoshiaki Kawano, Tawfiq Arafat, Torsten Böhler, Mathias Winkler, Colin Cooper & Dmitri Pchejetski. (2016) Everolimus (RAD001) sensitizes prostate cancer cells to docetaxel by down-regulation of HIF-1α and sphingosine kinase 1. Oncotarget 7:49, pages 80943-80956.
Crossref
S. Hager, C.J. Ackermann, M. Joerger, S. Gillessen & A. Omlin. (2016) Anti-tumour activity of platinum compounds in advanced prostate cancer—a systematic literature review. Annals of Oncology 27:6, pages 975-984.
Crossref
Hakim Mahammedi, Eloise Planchat, Mélanie Pouget, Xavier Durando, Hervé Curé, Laurent Guy, Isabelle Van-Praagh, Laurent Savareux, Marc Atger, Mathilde Bayet-Robert, Emilie Gadea, Catherine Abrial, Emilie Thivat, Philippe Chollet & Jean-Christophe Eymard. (2016) The New Combination Docetaxel, Prednisone and Curcumin in Patients with Castration-Resistant Prostate Cancer: A Pilot Phase II Study. Oncology 90:2, pages 69-78.
Crossref
Mohan Hingorani, Russell Morgan, Andrew Robertson, Richard Khafagy & Simon Hawkyard. (2014) UK single centre experience of rare and atypical variant of castrate-resistant prostate cancer: Poorly differentiated neuroendocrine small-cell carcinoma. Journal of Clinical Urology 8:1, pages 19-29.
Crossref
Hai Tao WangYan Hong YaoBao Guo LiYong TangJi Wu ChangJiao Zhang. (2014) Neuroendocrine Prostate Cancer (NEPC) Progressing From Conventional Prostatic Adenocarcinoma: Factors Associated With Time to Development of NEPC and Survival From NEPC Diagnosis—A Systematic Review and Pooled Analysis. Journal of Clinical Oncology 32:30, pages 3383-3390.
Crossref
Rosa Nadal, Michael Schweizer, Oleksandr N. Kryvenko, Jonathan I. Epstein & Mario A. Eisenberger. (2014) Small cell carcinoma of the prostate. Nature Reviews Urology 11:4, pages 213-219.
Crossref
Ana M. Aparicio, Andrea L. Harzstark, Paul G. Corn, Sijin Wen, John C. Araujo, Shi-Ming Tu, Lance C. Pagliaro, Jeri Kim, Randall E. Millikan, Charles Ryan, Nizar M. Tannir, Amado J. Zurita, Paul Mathew, Wadih Arap, Patricia Troncoso, Peter F. Thall & Christopher J. Logothetis. (2013) Platinum-Based Chemotherapy for Variant Castrate-Resistant Prostate Cancer. Clinical Cancer Research 19:13, pages 3621-3630.
Crossref
M. Oukabli, L. Mpiga Ekambou, A. Boudhas & A. Albouzidi. (2012) Impact pronostique et thérapeutique de la différenciation neuroendocrine au sein de l’adénocarcinome prostatique: mise au pointPrognostic and therapeutic impact of neuroendocrine differentiation in prostate adenocarcinoma: an update. Journal Africain du Cancer / African Journal of Cancer 4:2, pages 108-113.
Crossref
Dmitri Pchejetski, Torsten Böhler, Justin Stebbing & Jonathan Waxman. (2011) Therapeutic potential of targeting sphingosine kinase 1 in prostate cancer. Nature Reviews Urology 8:10, pages 569-578.
Crossref
M.M. Regan, E.K. O'Donnell, W.K. Kelly, S. Halabi, W. Berry, S. Urakami, N. Kikuno & W.K. Oh. (2010) Efficacy of carboplatin–taxane combinations in the management of castration-resistant prostate cancer: a pooled analysis of seven prospective clinical trials. Annals of Oncology 21:2, pages 312-318.
Crossref
Ashley Brick, Junyang Niu, Jiaoti Huang & William K. Oh. 2010. Drug Management of Prostate Cancer. Drug Management of Prostate Cancer 153 161 .
Lorelei Mucci & Edward Giovannucci. 2010. Preventive Nutrition. Preventive Nutrition 195 218 .
Y. Loriot, C. Massard, M. Gross-Goupil, M. Di Palma, B. Escudier, A. Bossi & K. Fizazi. (2009) Combining carboplatin and etoposide in docetaxel-pretreated patients with castration-resistant prostate cancer: a prospective study evaluating also neuroendocrine features. Annals of Oncology 20:4, pages 703-708.
Crossref
Mark T. Fleming, Guru Sonpavde, G. Varuni Kondagunta, Matthew D. Galsky, Thomas E. Hutson & Cora N. Sternberg. (2009) Systemic therapy and novel agents for metastatic castration resistant prostate cancer. Update on Cancer Therapeutics 3:3, pages 133-145.
Crossref
Lilach Agemy, Alon Harmelin, Tova Waks, Ilan Leibovitch, Tatyana Rabin, M. Raphael Pfeffer & Zelig Eshhar. (2008) Irradiation enhances the metastatic potential of prostatic small cell carcinoma xenografts. The Prostate 68:5, pages 530-539.
Crossref
Jorge L. Yao, Jiaoti Huang & P. Anthony di Sant’Agnese. (2008) Small cell carcinoma of the prostate. Diagnostic Histopathology 14:3, pages 117-121.
Crossref
Susan F Slovin. (2007) Does small-cell phenotype predict the natural history of prostate cancer? A case study in disease behavior. Nature Clinical Practice Oncology 4:9, pages 551-554.
Crossref
William K. Oh, Miah‐Hiang Tay & Jiaoti Huang. (2006) Is there a role for platinum chemotherapy in the treatment of patients with hormone‐refractory prostate cancer?. Cancer 109:3, pages 477-486.
Crossref
T S Mantoni, G Reid & M D Garrett. (2006) Androgen receptor activity is inhibited in response to genotoxic agents in a p53-independent manner. Oncogene 25:22, pages 3139-3149.
Crossref
Guru Sonpavde, Thomas E. Hutson & William R. Berry. (2006) Hormone refractory prostate cancer: Management and advances. Cancer Treatment Reviews 32:2, pages 90-100.
Crossref
Aurélie Cabrespine, Laurent Guy, Françoise Gachon, Hervé Curé, Philippe Chollet & Jacques-Olivier Bay. (2006) Circulating Chromogranin A and Hormone Refractory Prostate Cancer Chemotherapy. The Journal of Urology 175:4, pages 1347-1352.
Crossref
William K. Oh, Elizabeth Hagmann, Judith Manola, Daniel J. George, Timothy D. Gilligan, Joseph O. Jacobson, Matthew R. Smith, Donald S. Kaufman & Philip W. Kantoff. (2005) A Phase I Study of Estramustine, Weekly Docetaxel, and Carboplatin Chemotherapy in Patients with Hormone-Refractory Prostate Cancer. Clinical Cancer Research 11:1, pages 284-289.
Crossref
Harish S Hosalkar, Kathleen M Henderson, Arthur Weiss, Rakesh Donthineni & Richard D Lackman. (2004) Chemotherapy for Bone Sarcoma Does Not Affect Fertility Rates or Childbirth. Clinical Orthopaedics & Related Research 428, pages 256-260.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.